| HOME >> MEDICINE >> TECHNOLOGY |
BRANFORD, Conn., Nov. 26 /PRNewswire-FirstCall/ -- CuraGen Corporation
(Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on
oncology, and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced
today that updated preliminary clinical trial results from the Phase II
study of belinostat for T-cell lymphomas, and new preclinical data
evaluating belinostat on pediatric leukemia cell lines, will be presented
at the 2007 American Society of Hematology (ASH) 49th Annual Meeting in
Atlanta, GA, on Monday, December 10, 2007.
The presentation details are as follows:
Title: Belinostat (PXD101) in Patients with Recurrent or Refractory
Peripheral or Cutaneous T-Cell Lymphoma: Results of a Phase
II Study
Date/Time: Monday, December 10, 2007, 5:00 - 7:00 PM EST
Session: Lymphoma: Chemotherapy, excluding Pre-Clinical Models-
Diffuse Large Cell Lymphoma and T-Cell Lymphoma
Poster board: 672-II
Abstract: 3453
Title: Investigation of the Efficacy of PXD101 (Belinostat) on
Primary Leukaemic Cells and Cell Lines as a Novel Agent for
Childhood Acute Lymphoblastic Leukaemia (ALL)
Date/Time: Monday, December 10, 2007, 5:00 - 7:00 PM EST
Session: Acute Lymphocytic Leukemia: Biology and Pathophysiology
Poster board: 12-III
Abstract: 2793
These abstracts are currently available online at
http://www.abstracts2view.com/hem07. Following their presentation on
December 10, 2007, reprints of the posters will be made available on
CuraGen's website at '/>"/>
| SOURCE CuraGen Corporation Copyright©2007 PR Newswire. All rights reserved |